Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011849 (diabetes)
 277,896 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

BAYo1248 and BAYm1099 are two new alpha-glucosidase inhibitors. Postprandial glucose tolerance was significantly improved and postprandial insulin requirements were significantly reduced as compared to placebo after breakfast and lunch when 20 mg BAYo1248 were administered prior to breakfast and after breakfast, lunch and dinner when 50 mg BAYm1099 were given prior to all three main meals. Postprandial breath H2 concentrations were mildly increased when these alpha-glucosidase inhibitors were given and no patient complained of any adverse effects (such as flatulence, abdominal pain or diarrhea). BAYo1248 and BAYm1099 might be useful adjuncts to insulin in the treatment of patients with insulin-dependent diabetes mellitus.
 ...
PMID:Effects of two new alpha-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus. 352 Jan 33

We investigated the hormonal and metabolic response to a 100-g sucrose load given 15 min after adaptation to moderate-intensity (50% VmaxO2) long-duration (4-h) exercise in healthy volunteers. The effect of a 100-mg dose of the alpha-glucosidase inhibitor Acarbose ingested with the sucrose load was also investigated. "Naturally labeled [13C] sucrose" was used to follow the conversion to expired-air CO2 of the sugar ingested by isotope-ratio mass spectrometry. Circulating hormone and metabolite data were obtained in nine subjects, and indirect calorimetry and stable isotope methodology were applied to six of them. Under placebo, 93 +/- 4 g sucrose were entirely oxidized during the 4 h of exercise, total carbohydrate utilization was 235 +/- 14 g, endogenous carbohydrate utilization was 142 +/- 13 g, and total lipid oxidation was 121 +/- 7 g. A single oral dose of 100 mg Acarbose ingested with the sucrose load did not significantly modify total carbohydrate (239 +/- 2 g/4 h) or lipid (122 +/- 6 g/4 h) oxidation. In contrast, sucrose oxidation was reduced to 53 +/- 6 g/4 h and endogenous carbohydrate utilization increased to 186 +/- 7 g/4 h. Reduction of the rises in blood glucose and fructose and of the increases in plasma insulin and C peptide under Acarbose confirmed these effects, whereas lower circulating levels of alanine suggested a higher rate of gluconeogenesis. These data show that a 100-g glucose load ingested soon after initiation of exercise is a perfect available metabolic substrate.(ABSTRACT TRUNCATED AT 250 WORDS)
Diabetes 1986 Nov
PMID:Utilization of oral sucrose load during exercise in humans. Effect of the alpha-glucosidase inhibitor acarbose. 353 Aug 58

The alpha-glucosidase inhibitor BAY m 1099, a deoxynojirimycin derivative, was studied in sulfonylurea-treated type II diabetic patients using a placebo-controlled double-blind cross-over design. Given in two daily doses the inhibitor smoothened the blood glucose profile by lowering significantly post-prandial blood glucose peaks. Fasting and daily mean blood glucose levels measured as the area under the blood glucose curves were however not influenced significantly. This might be due to the short duration of the treatment periods or the low dosage of the drug. Abdominal side effects were negligible. The alpha-glucosidase inhibitor BAY m 1099 might become a useful therapeutic tool in addition to sulfonylurea treatment in type II diabetes.
 ...
PMID:Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients. 353 37

Miglitol is an alpha-glucosidase inhibitor which lowers blood glucose and insulin concentrations in healthy volunteers after a starch meal. It also lowers blood glucose concentrations after a starch meal in patients with non-insulin-dependent diabetes mellitus, but under these circumstances insulin is unaffected. We have studied the effect of miglitol after a glucose load in six healthy male volunteers. Although one would expect an alpha-glucosidase inhibitor to have no effect on blood glucose concentrations after a glucose load, miglitol produced a significant decrease in blood glucose concentrations after the absorption peak. This could be due to enhancement of insulin effects or to depression of anti-insulin factors.
 ...
PMID:Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase. 354 25

With use of the alpha-glucosidase inhibitor bay g 5421 (acarbose), it is possible to improve glycemic profiles in diabetics without a concomitant increase in insulin levels or weight reduction. We have taken advantage of this feature to test whether an improvement in glycemic control alone can ameliorate some of the known abnormalities of type II diabetes (ie, impaired insulin secretion, elevated rate of basal hepatic glucose output, peripheral insulin resistance). We have studied eight type II diabetics (mean +/- SE fasting serum glucose 193 +/- 25 mg/dL) before and after 2 weeks of acarbose therapy (100 mg with each meal). Assessment of endogenous insulin secretion, peripheral and hepatic insulin sensitivity, and adipose tissue lipoprotein lipase (ATLPL) activity were performed. Results showed significant lowering of postprandial glucose excursions above basal but no change in basal serum glucose levels, marked reduction in fasting and day-long triglyceride levels and in spite of a reduction in ATLPL activity, an increase in hepatic sensitivity to insulin's ability to suppress hepatic glucose output, and no effect on peripheral insulin sensitivity. In conclusion, inhibition of carbohydrate digestion with alpha-glucosidase inhibitors ameliorates many of the metabolic abnormalities in type II (noninsulin-dependent diabetics), suggesting that agents of this type can be of therapeutic value.
 ...
PMID:The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics. 355 48

In patients with diabetes mellitus, delayed increases in circulating insulin levels followed by prolonged hyperinsulinemia due to slow absorption of subcutaneously administered insulin hinders maintenance of euglycemia. To determine whether a delay in carbohydrate absorption would increase the effectiveness of subcutaneous insulin in controlling postprandial hyperglycemia in patients with insulin-dependent diabetes mellitus and whether it could allow insulin to be taken immediately prior to meals, the effects of an alpha-glucosidase inhibitor (Acarbose Boyer AG, Wuppertal, Germany) on postprandial plasma glucose profiles were determined in six subjects with insulin-dependent diabetes when a subcutaneous insulin infusion was started immediately or 30 minutes prior to meal ingestion. When 25% less insulin (9 v 12 units) was given along with Acarbose 30 minutes prior to meal ingestion, postprandial hyperglycemia decreased by 45% (areas under the curve, AUC, 8193 +/- 1960 v 14783 +/- 2260 mg/dL X min, P less than 0.02). When similar amounts of insulin (12 units) were given immediately prior to meal ingestion, postprandial hyperglycemia decreased 55% (AUC 6187 +/- 2240 v 13642 +/- 1579 mg/dL X min, P less than 0.001). These results indicate that delay in carbohydrate absorption improves the effectiveness of subcutaneous insulin in controlling postprandial hyperglycemia in patients with insulin-dependent diabetes mellitus and may permit satisfactory postprandial glycemic control when insulin is administered immediately prior to meal ingestion. Thus, an agent like Acarbose, which delays carbohydrate absorption, may be useful as an adjunct to insulin in the treatment of diabetes mellitus.
 ...
PMID:alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus. 388 97

The lysosomal enzymes cathepsin D (E.C. 3.4.23.5), alpha-glucosidase (E.C. 3.2.1.20) and beta-galactosidase (E.C. 3.2.1.23), potentially involved in the breakdown of the peptide component and the disaccharide units of basement membrane glycoproteins, were studied in the kidney cortex and liver of streptozotocin-diabetic mice. In the liver of diabetic mice, as compared to controls, an increase was found for the total activity (measured in frozen-thawed homogenates) of cathepsin D (+135%, P less than 0.01) and beta-galactosidase (+32%, P less than 0.05). In the kidney a decrease was observed for both the free activity (measured in 12,000 g supernatant) and the total activity of these two enzymes (cathepsin D: -62% and -24%; beta-galactosidase: -29% and -23%; P less than 0.05 in all instances). Alpha-glucosidase did not show significant changes in either tissues. Total protein content of the two organs did not change significantly with diabetes and therefore cannot account for the enzyme alterations observed. These data indicate that the response of kidney to diabetes is opposite to that of liver (decrease versus increase in catabolic enzymes), and suggest decreased degradation of basement membrane in some tissues in diabetes, which may contribute to the thickening of basement membrane and therefore to the development of microangiopathy.
 ...
PMID:Cathepsin D and other hydrolases in the kidney of streptozotocin-diabetic mice. Possible relevance to microangiopathy. 393 Mar 80

The changes of the transmural electrical potential difference (delta PD) evoked by infusion of glucose, maltose and sucrose and the disaccharidase activities in the everted intestine were studied in diabetic rats. After the induction of diabetes by streptozotocin, delta PDs evoked by sugars and the enzyme activities were observed in the jejunum and ileum. delta PDs evoked by glucose, maltose and sucrose markedly increased both in the jejunum and ileum of diabetic rats. The Kt values for these sugars in diabetic rats were the same as those of control rats. The Vmax values were significantly increased in the ileum of diabetic rats. Maltase and sucrase activities in the ileum increased in diabetic rats. Highly significant linear correlations were found between the delta PDs evoked by glucose and the delta PDs evoked by maltose or sucrose both in the jejunum and ileum of control and diabetic rats. However, delta PDs evoked by maltose and sucrose did not correlate with maltase and sucrase activities in the jejunum. In the ileum, delta PDs evoked by sucrose correlated with the sucrase activity which was very low. These results suggest that the increase of transport of glucose derived from disaccharides in the diabetes induced by streptozotocin is mainly due to the increased activity of the glucose transport system, but not due to the increase of disaccharidase activities.
 ...
PMID:Changes of sugar-evoked transmural potential differences in intestine of rats with streptozotocin-induced diabetes. 406 65

The effects of sucrose and Acarbose (alpha-glucosidase inhibitor) feeding on the development of diabetes were studied in streptozotocin-treated rats. Rats were raised on four different dietary regimens, viz, a sucrose diet (46% of the total weight in the form of sucrose, 24% as starch), a starch diet (70% as starch), a standard diet (laboratory chow: Oriental Yeast Co.) or an Acarbose diet (a standard diet containing 75 mg Acarbose/100g diet) for a week followed by an intraperitoneal injection of streptozotocin (70 mg/kg). Development of diabetes was determined by urinary and blood glucose levels (more than 250 mg/dl). The incidence of diabetes in the groups of rats fed on sucrose, starch, standard, and Acarbose diets was 100%, 80%, 70% and 47.6%, respectively. The development of diabetes was accelerated by sucrose feeding and depressed by Acarbose feeding. There was mild diabetes in rats fed on Acarbose diet. The sucrose feeding caused a marked increase of disaccharidase activities in the proximal part of the intestine and in the apical part of the villus-crypt gradient of epithelial cells. The Acarbose feeding caused a significant decrease of disaccharidase activities. The changes in protein content of the sucrase-isomaltase complex appeared to be in parallel with those of disaccharidase activities. These results suggest that intestinal disaccharidase activities are involved in the development of experimental diabetes induced by streptozotocin.
 ...
PMID:Effect of sucrose and Acarbose feeding on the development of streptozotocin-induced diabetes in the rat. 621 54

Three therapeutic inhibitors of vertebrate alpha-glucosidases recently assayed in research on diabetes control, show high inhibitory potencies towards the p-NP-alpha-D-glucosidase activity of honeybee haemolymph. BAYe 4609 is an allosteric V-type (pure non-competitive) inhibitor with: Ki congruent to K'i congruent to I50 congruent to 180 micro M; n = 1.17; ni = 1.15 BAYg 5421, an hydrolysis derivative of the former, is a mixed allosteric inhibitor with: Ki congruent to 0.17 micro M; K'i congruent to 0.85 micro M; I50 congruent to 0.38 micro M; n = 1.19; ni = 1.25. BAYn 5595 isd a pure competitive Michaelian inhibitor with: Ki = 15 micro M; I50 congruent to 23 micro M. All these properties reveal similarities to and differences from those of the natural inhibitors of the enzyme and analogies with their action on vertebrate enzymes. Accordingly, correlations have been emphasized between the structure and the activity of these inhibitors which finally lead to propositions of structures for new active molecules.
 ...
PMID:Kinetic study of the inhibition of the honeybee haemolymph apha-glucosidase in vitro by BAYe 4609, BAYg 5421 and BAYn 5595. 621 20


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>